Optonol Ltd.

Optonol (acquired by Alcon/Novartis) developed Ex-PressTM, a microscopic glaucoma shunt that is transforming glaucoma therapy globally on its way to becoming the gold standard in glaucoma surgery.


Medigus (TASE: MDGS) is developing endoscopy systems for the treatment of GERD (Gastro Esophageal Reflex Disease) and other diseases of the digestive system.


XTL (NASDAQ:XTLB; TASE: XTL) is developing therapeutics for the treatment of diabetic neuropathic pain and HCV.


ColBar (acquired by Johnson & Johnson) is a biomaterials company specializing in reconstructive medicine and tissue engineering.


EasyLap’s mission is to develop supporting, easy to use devices, which will simplify and shorten laparoscopic procedures, thus enabling more widespread use of this superior, yet not exploited, surgical technique.


D-Pharm (TASE: DPRM) discovers and develops lipid-based drugs for the treatment of central nervous system disorders and cancer. The Company has developed two unique platform technologies that generate lipid–like medicines which utilize lipid specific properties and lipid-related pathways in living cells.

Mazor Robotics

Mazor Robotics (NASDAQ:MZOR): RenaissanceTM, its robotic guidance system used worldwide in thousands of spine procedures, is transforming spinal surgery from freehand to highly accurate, state-of-the-art operations.


Syneron (NASDAQ: ELOS) develops, manufactures and markets medical aesthetic devices based on the ELOS combined energy technology (Electro-Optical Synergy) using Bi-Polar Radio Frequency and Light. The company’s products have superior safety features comparing to other devices on the market, with equal or even better efficacy